Richard Polisson, M.D., MHSc

Chief Medical Officer

Richard Polisson, M.D., MHSc brings extensive experience from both industry and academia. Prior to Artax, Dr. Polisson was the Senior Vice President and Head of Translational Medicine at Sanofi-Genzyme Research and Development Center, responsible for managing and aligning research physicians with projects at the earliest stages of discovery research and directing the review and endorsement of all translational medicine inputs (e.g., disease indication selection, target credentialing, biomarker plan, “Proof of Concept” studies, and early human trials) across Rare/Genetic Diseases, Multiple Sclerosis/Neurology, Immune-Mediated Diseases, and Fibrosis and Tissue Repair.  Dr. Polisson came to the biotech and pharmaceutical industry 22 years ago from Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), where he was Associate Professor of Medicine, Clinical Director of the Arthritis Unit, and Chair of the Mallinckrodt Clinical Research Unit Scientific Advisory Committee. Dr. Polisson has formal master’s level training in the quantitative methods of clinical investigation and has 30 years of experience in clinical and translational research, beginning initially at the National Cancer Institute/NIH, and subsequently in academia at Duke and MGH/HMS.  Dr. Polisson received his BS from Yale University and his MD from Duke University School of Medicine.  He is the author of more than 120 manuscripts, chapters, and abstracts.